Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

StratosPHere: Optimal Biomarkers to Ascertain Target Engagement in Therapies Targeting the BMPR2 Pathway in Pulmonary Arterial Hypertension (PAH)

NCT05767918 is registered in ClinicalTrials.gov with Papworth Hospital NHS Foundation Trust as lead sponsor.

NCT NCT05767918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05767918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
StratosPHere: Optimal Biomarkers to Ascertain Target Engagement in Therapies Targeting the BMPR2 Pathway in Pulmonary Arterial Hypertension (PAH)
Lead sponsor
Papworth Hospital NHS Foundation Trust
Phase
Observational
Overall status
Completed
Start date
April 14, 2021
Completion date
September 30, 2022
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary arterial hypertension, pulmonary arterial hypertension, pulmonary hypertension, respiratory disease